Purpose: To describe the clinical presentation, management, and histopathological results of a congenital eccrine hidrocystoma.
Observations: A 4-year-old healthy boy presented with left upper eyelid ptosis and superonasal painless mass since birth. Computed tomography showed a hypodense cystic lesion located in the extraconal orbital compartment medially. Following complete excision, histopathology revealed an eccrine hidrocystoma.
Conclusions And Importance: Orbital eccrine hidrocystomas should be considered in the differential diagnosis of orbital cystic masses in the pediatric age group.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880129 | PMC |
| http://dx.doi.org/10.1016/j.ajoc.2019.100570 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary Mucinous Eccrine Carcinoma in Nasomaxillary Region: a Rare Case Report and Management Insights.
Indian J Otolaryngol Head Neck Surg
April 2024
Department of Pathology, Hitkarini Dental College and Hospital, Jabalpur, India.
Primary Mucinous eccrine carcinoma (MEC) is a rare malignant neoplasm of skin believed to arise from eccrine sweat gland commonly with periocular involvement. Here we report a case of 60-year male with a recurrence of unilateral nasomaxillary mass and epiphora. Imaging suggested nasolacrimal duct as probable site of origin.
View Article and Find Full Text PDFEccrine spiradenoma of eyelid - a rare tumor at an unusual location with literature review.
Orbit
February 2024
Orbit, Oculoplasty, Reconstructive & Aesthetic Services, Aditya Birla Sankara Nethralaya (A Unit of Medical Research Foundation, Chennai, India), Kolkata, India.
Article Synopsis
- A case involved a 39-year-old Indian woman with a painless nodular mass on her upper eyelid that had been growing for four years.
- After surgical removal, the mass was identified as eccrine spiradenoma, showing a low Ki-67 index, and the patient was doing well with no recurrence two months later.
Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin.
J Cutan Pathol
May 2024
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Article Synopsis
- Enfortumab vedotin (EV) is a targeted therapy for urothelial carcinoma, and this study evaluates its effectiveness for treating certain skin tumors by assessing Nectin-4 expression.
- Researchers analyzed various skin adnexal carcinomas and benign tumors through immunohistochemical staining, finding that malignant tumors had significantly higher Nectin-4 expression than benign ones.
- The study concludes that since many cutaneous adnexal carcinomas, particularly sebaceous carcinomas, exhibit high Nectin-4 levels, EV could be a viable treatment option for these cancers.
A novel case of recurrent cylindroma of the orbit.
Orbit
November 2023
Department of Ophthalmology and Visual Sciences, University of Adelaide, North Terrace, Australia.
Cylindroma is a rare benign tumour of eccrine origin that has not been previously reported within the orbit. We report a case of a recurrent orbital cylindroma following incomplete excision. A 75-year-old female presented with a recurrent left inferomedial orbital mass.
View Article and Find Full Text PDFPorocarcinoma with orbital metastasis, a case report with review of literature.
Orbit
October 2024
Orbit and Oculofacial Surgery/Ophthalmic Oncology, Department of Ophthalmology, National University Hospital, Singapore, Singapore.
We present a patient who presented with an orbital mass lesion which was a metastatic lesion from a porocarcinoma of the scalp with progressive deterioration of the patient.A 78-year-old male presented with functional decline and a rapidly growing scalp lesion of 3 months duration. In addition to the scalp lesion, Computed Tomography showed an incidental finding of a left lateral orbital wall tumour.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!